Q3 2024 Holdings
Filed 2024-11-14 | 62 holdings | $115.2M | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Bristol-Myers Squibb Co(BMY) | COM | 110122108 | $35.5M | 686,182 | 30.8% |
| Biodesix Inc | COM | 09075X108 | $9.9M | 5,541,176 | 8.6% |
| Acadia Pharmaceuticals Inc(ACAD) | COM | 004225108 | $6.2M | 400,400 | 5.3% |
| Elutia Inc(ELUT) | COM | 05479K106 | $5.0M | 1,321,215 | 4.4% |
| United Therapeutics Corp(UTHR) | COM | 91307C102 | $3.6M | 10,000 | 3.1% |
| Prothena Corp PLC(PRTA) | SHS | G72800108 | $3.5M | 209,574 | 3.0% |
| Neurocrine Biosciences Inc(NBIX) | COM | 64125C109 | $3.5M | 30,240 | 3.0% |
| Corcept Therapeutics Inc(CORT) | COM | 218352102 | $3.4M | 74,000 | 3.0% |
| Harrow Health Inc(HROW) | COM | 415858109 | $3.3M | 72,910 | 2.8% |
| Quidelortho Corp | COM | 74838J101 | $3.1M | 67,619 | 2.7% |
| Foghorn Therapeutics Inc(FHTX) | COM | 344174107 | $3.0M | 320,930 | 2.6% |
| Axogen Inc(AXGN) | COM | 05463X106 | $2.8M | 197,000 | 2.4% |
| Phreesia Inc(PHR) | COM | 71944F106 | $2.6M | 114,700 | 2.3% |
| Stoke Therapeutics Inc(STOK) | COM | 86150R107 | $2.6M | 210,000 | 2.2% |
| Protagonist Therapeutics Inc(PTGX) | COM | 74366E102 | $2.2M | 48,000 | 1.9% |
| Travere Therapeutics Inc(TVTX) | COM | 89422G107 | $2.1M | 148,000 | 1.8% |
| Masimo Corp(MASI) | COM | 574795100 | $2.0M | 15,280 | 1.8% |
| Ovintiv Inc(OVV) | COM | 69047Q102 | $2.0M | 52,200 | 1.7% |
| Docgo Inc(DCGO) | COM | 256086109 | $1.7M | 515,000 | 1.5% |
| Castle Biosciences Inc(CSTL) | COM | 14843C105 | $1.7M | 58,000 | 1.4% |
| Alkermes PLC(ALKS) | SHS | G01767105 | $1.4M | 50,000 | 1.2% |
| EQT Corporation(EQT) | COM | 26884L109 | $1.3M | 34,619 | 1.1% |
| Alphatec Holdings Inc(ATEC) | COM | 02081G201 | $1.1M | 198,000 | 1.0% |
| Kalvista Pharmaceuticals Inc(KALV) | COM | 483497103 | $949.6K | 82,000 | 0.8% |
| Kiniksa Pharmaceuticals LTD | COM | G5269C101 | $749.7K | 30,000 | 0.7% |
| 10X Genomics Inc(TXG) | CL A COM | 88025U109 | $677.4K | 30,000 | 0.6% |
| Halozyme Therapeutics Inc(HALO) | COM | 40637H109 | $572.4K | 10,000 | 0.5% |
| Accelerate Diagnostics Inc | COM | 00430H102 | $556.2K | 325,239 | 0.5% |
| Cytokinetics Inc(CYTK) | COM | 23282W605 | $528.0K | 10,000 | 0.5% |
| Inhibrx Biosciences Inc(INBX) | COM | 45720N103 | $502.8K | 32,110 | 0.4% |
| Keros Therapeutics Inc(KROS) | COM | 492327101 | $406.5K | 7,000 | 0.4% |
| Apellis Pharmaceuticals Inc(APLS) | COM | 03753U106 | $403.8K | 14,000 | 0.4% |
| Treace Medical Concepts Inc(TMCI) | COM | 89455T109 | $396.4K | 68,350 | 0.3% |
| Xenon Pharmaceuticals Inc(XENE) | COM | 98420N105 | $393.7K | 10,000 | 0.3% |
| Karyopharm Therapeutics Inc(KPTIEUR) | COM | 48576U106 | $390.0K | 469,832 | 0.3% |
| Coherus Biosciences Inc(CHRS) | COM | 19249H103 | $386.9K | 372,000 | 0.3% |
| Arvinas Inc(ARVN) | COM | 04335A105 | $369.5K | 15,000 | 0.3% |
| Progyny Inc(PGNY) | COM | 74340E103 | $368.7K | 22,000 | 0.3% |
| Biohaven Pharmaceutical Holding Co LTD(BHVN) | COM | G11196105 | $368.0K | 7,365 | 0.3% |
| Axsome Therapeutics Inc(AXSM) | COM | 05464T104 | $359.5K | 4,000 | 0.3% |
| Cullinan Oncology Inc(CGEM) | COM | 230031106 | $334.8K | 20,000 | 0.3% |
| Wave Life Sciences LTD(WVE) | SHS | Y95308105 | $328.0K | 40,000 | 0.3% |
| Springworks Therapeutics Inc | COM | 85205L107 | $320.4K | 10,000 | 0.3% |
| Novocure LTD(NVCR) | ORD SHS | G6674U108 | $312.6K | 20,000 | 0.3% |
| Sarepta Therapeutics Inc(SRPT) | COM | 803607100 | $312.2K | 2,500 | 0.3% |
| Biocryst Pharmaceuticals Inc(BCRX) | COM | 09058V103 | $304.0K | 40,000 | 0.3% |
| Amicus Therapeutics Inc(FOLD) | COM | 03152W109 | $299.0K | 28,000 | 0.3% |
| Blueprint Medicines Corp(2L9) | COM | 09627Y109 | $249.8K | 2,700 | 0.2% |
| Xencor Inc(XNCR) | COM | 98401F105 | $247.4K | 12,300 | 0.2% |
| Gossamer BIO Inc(GOSS) | COM | 38341P102 | $136.3K | 138,176 | 0.1% |